KEYNOTE-564. Adjuvant Rx of intermediate/high-risk RCC with pembro. vs. placebo. Few Rx options for pts at risk to recur after nephx. DFS is key EP. “Important as this is the likely space for use of these drugs” – Powles. #EAU18
KEYNOTE-564. Adjuvant Rx of intermediate/high-risk RCC with pembro. vs. placebo. Few Rx options for pts at risk to recur after nephx. DFS is key EP. “Important as this is the likely space for use of these drugs” – Powles. #EAU18